dc.contributor.author | El Missiry, Mohamed | |
dc.contributor.author | Hjorth-Hansen, Henrik | |
dc.contributor.author | Richter, Johan | |
dc.contributor.author | Olson-Strömberg, Ulla | |
dc.contributor.author | Stenke, Leif | |
dc.contributor.author | Porkka, Kimmo | |
dc.contributor.author | Kreutzman, Anna | |
dc.contributor.author | Mustjoki, Satu | |
dc.date.accessioned | 2018-06-06T12:54:55Z | |
dc.date.available | 2018-06-06T12:54:55Z | |
dc.date.created | 2017-06-15T14:03:17Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | PLoS ONE. 2017, 12:e0171041 (1), 1-17. | nb_NO |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/11250/2500629 | |
dc.description.abstract | n chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of tyrosine kinase inhibitor (TKI) treatment to predict therapy response. Fifty-two first-line TKI-treated CML patients were included (imatinib n = 26, dasatinib n = 21, nilotinib n = 5), and BCR-ABL1 transcript levels were measured at diagnosis (dg) and 1, 3, 6, 12, 18, 24, and 36 months. The fold change of the BCR-ABL1 transcripts at 1 month compared to initial BCR-ABL1 transcript levels was used to indicate early therapy response. In our cohort, 21% of patients had no decrease in BCR-ABL1 transcript levels after 1 month and were classified as poor responders. Surprisingly, these patients had lower BCR-ABL1 transcript levels at dg compared to responders (31% vs. 48%, p = 0.0083). Poor responders also significantly more often had enlarged spleen (55% vs. 15%; p<0.01) and a higher percentage of Ph+ CD34+CD38- cells in the bone marrow (91% vs. 75%, p<0.05). The major molecular response rates were inferior in the poor responders (at 12m 18% vs. 64%, p<0.01; 18m 27% vs. 75%, p<0.01; 24m 55% vs. 87%, p<0.01). In conclusion, early treatment response analysis defines a biologically distinct patient subgroup with inferior long-term outcomes. | nb_NO |
dc.language.iso | eng | nb_NO |
dc.publisher | PLOS | nb_NO |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia | nb_NO |
dc.type | Journal article | nb_NO |
dc.type | Peer reviewed | nb_NO |
dc.description.version | publishedVersion | nb_NO |
dc.source.pagenumber | 1-17 | nb_NO |
dc.source.volume | 12:e0171041 | nb_NO |
dc.source.journal | PLoS ONE | nb_NO |
dc.source.issue | 1 | nb_NO |
dc.identifier.doi | 10.1371/journal.pone.0171041 | |
dc.identifier.cristin | 1476417 | |
dc.description.localcode | © 2017 El Missiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | nb_NO |
cristin.unitcode | 194,65,15,0 | |
cristin.unitname | Institutt for klinisk og molekylær medisin | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |